News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Mineralys Therapeutics Announces publication – Ysios Capital
The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension Lorundrostat 50 mg once daily demonstrated clinically meaningful reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 and a 19.0 mmHg reduction at Week 12 Lorundrostat was generally well-tolerated; and
Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 – Ysios Capital
First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date Trial funded by a $14 million grant from California Institute for Regenerative Medicine Data from this bilateral trial, together with results from the previously announced Phase 3 EPIC study in unilateral MTLE, are intended to support a future
Mineralys results from pivotal Phase 3 Launch-HTN trial – Ysios Capital
Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting Lorundrostat 50 mg dosed once daily demonstrated clinically meaningful and sustained reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo
Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council – Ysios Capital
Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP) Scale Up call Funding to support commercialization of its groundbreaking bioresorbable vascular conduits EINDHOVEN, The Netherlands, 8 April 2025 - Xeltis, a leading developer of transformative implants that enable the natural creation of living and
CorWave appoints Dawn Sadlowski-Buisserez– Ysios Capital
Clichy, France, April 2nd, 2025 – CorWave, a French company developing and manufacturing innovative cardiac assist devices, announces the appointment of Dawn Sadlowski-Buisserez as Vice President of Operations. Dawn Sadlowski Buisserez brings extensive experience in implantable medical devices to support CorWave's production scale-up. Her expertise is a major asset for CorWave’s industrial development and its